IO BIOTECH ApS

The Company's principal activities IO Biotech ApS (in the following referred to as "IO Biotech" or the "Company") is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech has a pipeline of first-in-class immune modulating anti-cancer therapies based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic and has compounds in clinical development and late-stage preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class scientific and clinical advisory board.